Covered recipient · General Payments record
ZEHRA RIZVI
General Payments · PY2024
$332.51
- Reported across 9 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $332.51 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Almirall LLC | $121.16 | 1 |
| Neurocrine BioSciences, Inc. | $36.31 | 1 |
| Genentech USA, Inc. | $30.55 | 1 |
| SK Life Science, Inc. | $30.25 | 1 |
| GENZYME CORPORATION | $29.64 | 1 |
| Biogen, Inc. | $28.13 | 1 |
| MDD US Operations, LLC | $25.45 | 1 |
| Octapharma USA, Inc. | $17.00 | 1 |
| Acerta Pharma LLC | $14.02 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $332.51 | 9 |
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
Program year 2024
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Almirall LLC | $121.16 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120636817 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.02 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110514794 | CMS |
| Biogen, Inc. | $28.13 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104826220 | CMS |
| Genentech USA, Inc. | $30.55 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133136763 | CMS |
| GENZYME CORPORATION | $29.64 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140005624 | CMS |
| MDD US Operations, LLC | $25.45 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147769958 | CMS |
| Neurocrine Biosciences, Inc. | $36.31 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150817778 | CMS |
| Octapharma USA, Inc. | $17.00 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142318258 | CMS |
| SK Life Science, Inc. | $30.25 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154137142 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.